FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285097809> ?p ?o ?g. }

• W4285097809 endingPage "358.e7" @default.
• W4285097809 startingPage "358.e1" @default.
• W4285097809 abstract "The role of allogeneic hematopoietic cell transplantation (allo-HCT) followed by maintenance therapy in high-risk multiple myeloma (MM) remains controversial. We evaluated the efficacy of ixazomib maintenance therapy after reduced-intensity conditioning allo-HCT from HLA-matched donors in patients with high-risk MM. The primary study endpoint was progression-free survival (PFS) postrandomization, treated as a time to event. Secondary endpoints were grade II-IV and grade II-IV acute graft-versus-host-disease (GVHD), chronic GVHD, best response, disease progression, nonrelapse mortality (NRM), overall survival (OS), toxicity, infection, and health-related quality of life. In this phase 2, double-blinded, prospective multicenter trial, we randomized patients with high-risk MM (ie, those with poor-risk cytogenetics, plasma cell leukemia, or relapsing within 24 months after autologous HCT) to ixazomib (3 mg on days 1, 8, and 15) or placebo after allo-HCT. The conditioning regimen included fludarabine/melphalan/bortezomib with tacrolimus plus methotrexate for GVHD. Fifty-seven patients were enrolled, of whom 52 (91.2%) underwent allo-HCT and 43 (82.7%) were randomized to ixazomib versus placebo. At 21 months postrandomization, the ixazomib and placebo groups had similar PFS (55.3% versus 59.1%; P = 1.00) and OS (94.7% versus 86.4%; P = .17). The cumulative incidences of grade III-IV acute GVHD at 100 days (9.5% versus 0%) and chronic GVHD at 12 months (68.6% versus 63.6%) also were similar in the 2 groups. The secondary analysis showed that at 24 months post-allo-HCT, PFS and OS were 52% and 82%, respectively, with a corresponding NRM of 11.7%. These results demonstrate the safety and durable disease control with allo-HCT in high-risk MM patients. We could not adequately assess the efficacy of ixazomib maintenance because the trial terminated early owing to enrollment delays, but there was no indication of any impact on outcomes." @default.
• W4285097809 created "2022-07-14" @default.
• W4285097809 creator A5000618865 @default.
• W4285097809 creator A5002718187 @default.
• W4285097809 creator A5004466299 @default.
• W4285097809 creator A5004913924 @default.
• W4285097809 creator A5013895038 @default.
• W4285097809 creator A5029390145 @default.
• W4285097809 creator A5029801761 @default.
• W4285097809 creator A5031690184 @default.
• W4285097809 creator A5033550793 @default.
• W4285097809 creator A5040328429 @default.
• W4285097809 creator A5051149939 @default.
• W4285097809 creator A5058362903 @default.
• W4285097809 creator A5060783496 @default.
• W4285097809 creator A5062691289 @default.
• W4285097809 creator A5063351800 @default.
• W4285097809 creator A5068834306 @default.
• W4285097809 creator A5070096873 @default.
• W4285097809 creator A5086815330 @default.
• W4285097809 creator A5087799564 @default.
• W4285097809 creator A5091869303 @default.
• W4285097809 date "2023-06-01" @default.
• W4285097809 modified "2023-10-17" @default.
• W4285097809 title "A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial" @default.
• W4285097809 cites W121638319 @default.
• W4285097809 cites W1977166918 @default.
• W4285097809 cites W1977691688 @default.
• W4285097809 cites W2002324468 @default.
• W4285097809 cites W2009865521 @default.
• W4285097809 cites W2044436186 @default.
• W4285097809 cites W2047682926 @default.
• W4285097809 cites W2072077329 @default.
• W4285097809 cites W2084542540 @default.
• W4285097809 cites W2103973225 @default.
• W4285097809 cites W2104200322 @default.
• W4285097809 cites W2107854972 @default.
• W4285097809 cites W2121236166 @default.
• W4285097809 cites W2137062141 @default.
• W4285097809 cites W2144789671 @default.
• W4285097809 cites W2169288585 @default.
• W4285097809 cites W2486629951 @default.
• W4285097809 cites W2556333790 @default.
• W4285097809 cites W2737964630 @default.
• W4285097809 cites W2773887087 @default.
• W4285097809 cites W2774700270 @default.
• W4285097809 cites W2782992298 @default.
• W4285097809 cites W2904778784 @default.
• W4285097809 cites W2991132415 @default.
• W4285097809 cites W3017014502 @default.
• W4285097809 cites W3041320307 @default.
• W4285097809 cites W4211191410 @default.
• W4285097809 cites W4252175385 @default.
• W4285097809 cites W2080281636 @default.
• W4285097809 doi "https://doi.org/10.1016/j.jtct.2022.07.007" @default.
• W4285097809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35840087" @default.
• W4285097809 hasPublicationYear "2023" @default.
• W4285097809 type Work @default.
• W4285097809 citedByCount "1" @default.
• W4285097809 countsByYear W42850978092023 @default.
• W4285097809 crossrefType "journal-article" @default.
• W4285097809 hasAuthorship W4285097809A5000618865 @default.
• W4285097809 hasAuthorship W4285097809A5002718187 @default.
• W4285097809 hasAuthorship W4285097809A5004466299 @default.
• W4285097809 hasAuthorship W4285097809A5004913924 @default.
• W4285097809 hasAuthorship W4285097809A5013895038 @default.
• W4285097809 hasAuthorship W4285097809A5029390145 @default.
• W4285097809 hasAuthorship W4285097809A5029801761 @default.
• W4285097809 hasAuthorship W4285097809A5031690184 @default.
• W4285097809 hasAuthorship W4285097809A5033550793 @default.
• W4285097809 hasAuthorship W4285097809A5040328429 @default.
• W4285097809 hasAuthorship W4285097809A5051149939 @default.
• W4285097809 hasAuthorship W4285097809A5058362903 @default.
• W4285097809 hasAuthorship W4285097809A5060783496 @default.
• W4285097809 hasAuthorship W4285097809A5062691289 @default.
• W4285097809 hasAuthorship W4285097809A5063351800 @default.
• W4285097809 hasAuthorship W4285097809A5068834306 @default.
• W4285097809 hasAuthorship W4285097809A5070096873 @default.
• W4285097809 hasAuthorship W4285097809A5086815330 @default.
• W4285097809 hasAuthorship W4285097809A5087799564 @default.
• W4285097809 hasAuthorship W4285097809A5091869303 @default.
• W4285097809 hasConcept C126322002 @default.
• W4285097809 hasConcept C141071460 @default.
• W4285097809 hasConcept C142724271 @default.
• W4285097809 hasConcept C143998085 @default.
• W4285097809 hasConcept C203092338 @default.
• W4285097809 hasConcept C204787440 @default.
• W4285097809 hasConcept C207103383 @default.
• W4285097809 hasConcept C27081682 @default.
• W4285097809 hasConcept C2776364478 @default.
• W4285097809 hasConcept C2776694085 @default.
• W4285097809 hasConcept C2776755627 @default.
• W4285097809 hasConcept C2777478702 @default.
• W4285097809 hasConcept C2779263901 @default.
• W4285097809 hasConcept C2780108899 @default.
• W4285097809 hasConcept C2781098529 @default.
• W4285097809 hasConcept C2911091166 @default.
• W4285097809 hasConcept C44249647 @default.

• next